Moreover, since the overexpression of survivin confers chemo- and radioresistance in a variety of human cancers [21,22], we highlight the use of ·NO-releasing compounds as a promising hit and scaffold for future drug design for cancer treatments in which survivin is upregulated. The gene discussed is BIRC5; the disease is cancer.